1420006
USP
Levodopa Related Compound B
United States Pharmacopeia (USP) Reference Standard
Synonym(s):
DL-3-O-Methyldopa, 3-Methoxytyrosine
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H13NO4
CAS Number:
Molecular Weight:
211.21
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
levodopa
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
NC(Cc1cc(c(cc1)O)OC)C(=O)O
InChI
1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)
InChI key
PFDUUKDQEHURQC-UHFFFAOYSA-N
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
Also, for use with USP monographs such as:
- Carbidopa and Levodopa Orally Disintegrating Tablets
- Levodopa
- Carbidopa and Levodopa Tablets
- Carbidopa and Levodopa Extended-Release Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Angela Zampella et al.
Organic letters, 7(16), 3585-3588 (2005-07-29)
All stereoisomers of beta-methoxytyrosine (beta-OMeTyr), a stereo-undefined component of callipeltin A, were synthesized from L- and D-tyrosine. The stereochemistry of beta-OMeTyr in callipeltin A was determined to be 2R,3R by an oxidative procedure and Marfey's analysis. [structure: see text]
Eun-Sook Y Lee et al.
Neurochemical research, 33(3), 401-411 (2007-08-24)
Long-term treatment of L-dopa for Parkinson's disease (PD) patients induces adverse effects, including dyskinesia, on-off and wearing-off symptoms. However, the cause of these side effects has not been established to date. In the present study, therefore, 3-O-methyldopa (3-OMD), which is
Aiko Ishihara et al.
Hiroshima journal of medical sciences, 60(3), 57-62 (2011-11-08)
The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg
Eun-Sook Y Lee et al.
Neurotoxicology, 26(3), 361-371 (2005-06-07)
Long-term treatment of levodopa for Parkinson's disease (PD) patients is known to elevate homocysteine level in their plasma. The present study was designed to examine the possible neurotoxic effects of the increased homocysteine level on the dopaminergic system. Homocysteine was
Li-Hsuan Wang et al.
Phytotherapy research : PTR, 24(6), 852-858 (2009-11-27)
The impacts of caffeic acid (3,4-dihydroxycinnamic acid, CA) on the pharmacokinetics of levodopa (L-dopa) were studied in rabbits. A single dose of 5/1.25 mg kg(-1) L-dopa/carbidopa was administered alone or was co-administered with three different doses of caffeic acid (2.5
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service